Knight Therapeutics Inc.
GUD.TOTSXHealthcare● Active
$9.14
+$0.53(+6.16%)
Market Cap$896037158
P/E Ratio—
52W High$9.25
52W Low$5.66
Knight Therapeutics Inc. (GUD.TO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GUD.TO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.01B) | $0.00B | ($0.02B) | ($0.03B) | $0.02B |
| Depreciation & Amort. | $0.06B | $0.05B | $0.05B | $0.06B | $0.05B |
| Stock-Based Comp. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Change in Working Capital | $0.00B | ($0.02B) | ($0.03B) | ($0.01B) | $0.00B |
| Net Cash from Operations | $0.07B | $0.04B | $0.04B | $0.04B | $0.04B |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.03B) | ($0.01B) | ($0.03B) | ($0.22B) |
| Purchases of Investments | ($0.07B) | ($0.16B) | ($0.33B) | ($0.19B) | ($0.06B) |
| Sales of Investments | $0.11B | $0.20B | $0.35B | $0.15B | $0.18B |
| Net Cash from Investing | ($0.08B) | $0.02B | $0.03B | ($0.06B) | ($0.11B) |
| Financing Activities | |||||
| Common Stock Repurchased | ($0.01B) | ($0.01B) | ($0.05B) | ($0.03B) | ($0.06B) |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.02B | ($0.02B) | ($0.02B) | $0.03B | ($0.01B) |
| Net Cash from Financing | $0.01B | ($0.03B) | ($0.08B) | $0.00B | ($0.08B) |
| Free Cash Flow | |||||
| Free Cash Flow | $0.07B | $0.00B | $0.03B | $0.01B | ($0.18B) |
| FCF Margin %(computed) | 15.20% | 1.29% | 7.92% | 5.00% | -73.75% |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · CAD · B
Explore more Knight Therapeutics Inc. data
About Knight Therapeutics Inc. (GUD.TO) Cash Flow Statement
Knight Therapeutics Inc. generated operating cash flow of $0.07B and free cash flow of $0.07B for 2025 — a FCF margin of 15.20%. Capital expenditure was ($0.00B).
Frequently asked questions
GUD.TO · 4 questionsKnight Therapeutics Inc. generated free cash flow of $0.07B for 2025, up 1322.5% year-over-year.
GUD.TO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10